in 2023, will undergo a heart valve replacement surgery with implantation of a bioprosthesis.
in 2030 will require a heart valve replacement surgery with bioprosthesis implantation.
spent in the world, due to complications related to the limited durability of marketed heart valve bioprostheses.
Polyphenols are the core of the Facta® technology
BCI currently holds a portfolio of 4 international patents on the Facta®.
The conception of the Facta® technology began in 2015, with the identification of its core: a mixture of appropriately polyphenols chosen and used under specific conditions for treating bioprosthetic tissues. Polyphenols are naturally occurring molecules produced by the plant kingdom. More than 5,000 different types of polyphenols are known, but, only when some of them can act synergistically, the benefits demonstrated by the Facta® technology become apparent.
The mechanism of action
The role of the Facta® technology
The Facta® technology acts chemically on bioprostheses, forming permanent and stable bonds. The FACTA® technology acts as a "bridge" between the tissue proteins and aldehydes, permanently stabilizing and proving the entire structure a better mechanical behavior.
The glutaraldehyde is an aldehyde currently used by the manufacturing industry: while it is currently irreplaceable - both for the sterilization of the tissue and for its ability to make it mechanically stronger - this substance is known to have toxic effects when the bioprosthesis is implanted in humans. Glutaraldehyde is also responsible for the attraction of calcium salts present in the blood: the consequence is the calcification of the bioprosthesis, one of the many ways in which the tissue that constitutes it degenerates.
The Facta® technology detoxifies from the toxic residues of glutaraldehyde.
Finally, marketed bioprostheses treated using the FACTA® method have been shown both in vitro and in vivo to be protected against thrombus formation and to be inhospitable to bacteria: thus preventing infection, especially in the peri-operative phase. Among the side effects, the action of the treatment acts on the stabilization of the animal tissue, preventing the formation of tears, lacerations and abrasions.